Federal Jury Adopts Damages Calculation of Managing Principal Divya Mathur in Regeneron Pharmaceuticals’ Antitrust Case Win

June 4, 2025

Analysis Group was retained on behalf of Regeneron Pharmaceuticals, the plaintiff in an antitrust lawsuit against Amgen, another pharmaceutical company. Regeneron alleged that Amgen had undercut sales for Praluent, Regeneron’s cholesterol-reducing biologic, by illegally bundling its competing drug, Repatha, with rebates for or discounts on unrelated drugs. Regeneron claimed that the bundling violated the Sherman Act by making it economically unfeasible for Regeneron to continue to sell Praluent.

An Analysis Group team led by Managing Principal Aaron Yeater, Vice President Ishita Rajani, and Manager Kirsten Clinton supported Managing Principal Divya Mathur, who filed expert reports and testified at trial. Dr. Mathur assessed damages for Amgen’s alleged anticompetitive conduct.

A jury in the US District Court for the District of Delaware found in Regeneron’s favor, holding that Amgen’s bundling scheme violated the Sherman Act. The jury assessed compensatory damages of $135.6 million, the exact amount calculated by Dr. Mathur in her submissions, and punitive damages of $271.2 million.